NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Liminal BioSciences Inc (NASDAQ: LMNL)

 
LMNL Technical Analysis
5
As on 9th Jun 2023 LMNL STOCK Price closed @ 6.65 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.68 & Strong Buy for SHORT-TERM with Stoploss of 0.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

LMNLSTOCK Price

Open 6.75 Change Price %
High 6.75 1 Day -0.06 -0.89
Low 6.65 1 Week -0.25 -3.62
Close 6.65 1 Month -0.02 -0.30
Volume 3400 1 Year 5.60 533.33
52 Week High 6.95 | 52 Week Low 0.32
 
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
 
 
LMNL
Daily Charts
LMNL
Intraday Charts
Whats New @
Bazaartrend
LMNL
Free Analysis
 
LMNL Important Levels Intraday
RESISTANCE6.84
RESISTANCE6.78
RESISTANCE6.74
RESISTANCE6.70
SUPPORT6.60
SUPPORT6.56
SUPPORT6.52
SUPPORT6.46
 
LMNL Forecast April 2024
4th UP Forecast7.31
3rd UP Forecast7.1
2nd UP Forecast6.97
1st UP Forecast6.84
1st DOWN Forecast6.46
2nd DOWN Forecast6.33
3rd DOWN Forecast6.2
4th DOWN Forecast5.99
 
LMNL Weekly Forecast
4th UP Forecast7.38
3rd UP Forecast7.15
2nd UP Forecast7.00
1st UP Forecast6.86
1st DOWN Forecast6.44
2nd DOWN Forecast6.30
3rd DOWN Forecast6.15
4th DOWN Forecast5.92
 
LMNL Forecast2024
4th UP Forecast19.66
3rd UP Forecast15.49
2nd UP Forecast12.91
1st UP Forecast10.33
1st DOWN Forecast2.97
2nd DOWN Forecast0.39
3rd DOWN Forecast-2.19
4th DOWN Forecast-6.36
 
 
LMNL Other Details
Segment EQ
Market Capital 52701440.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
LMNL Address
LMNL
 
LMNL Latest News
 
Your Comments and Response on Liminal BioSciences Inc
 
LMNL Business Profile
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. Address: 440 Boulevard Armand-Frappier, Laval, QC, Canada, H7V 4B4
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service